Medtech Insight: News We're Watching: Globus Warning Letter, FDA Clears Traumagel, Reimbursement For Symplicity Spyral
The meeting, which will be facilitated by the Reagan-Udall Foundation, will provide those in the rare disease community the opportunity to provide input on the priorities of the hub. The FDA plans for the hub to work across rare diseases but especially focus on products intended for smaller populations or for less-understood diseases.